Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer
Part of paid clinical trials in Scottsdale, Arizona.
- Sponsor
- Mayo Clinic
- Study ID
- NCT02657928
- Phase
- PHASE2
- Status
- Completed
Conditions
- Estrogen Receptor Positive
- Postmenopausal
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma
- Recurrent Uterine Corpus Carcinoma
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Laboratory Biomarker Analysis — OTHERCorrelative studies
- Letrozole — DRUGGiven PO
- Ribociclib — DRUGGiven PO
Study Details
This phase II trial studies how well ribociclib and letrozole work in treating patients with estrogen receptor (ER) positive ovarian, fallopian tube, primary peritoneal, or endometrial cancer that has returned (come back) after a period of improvement. Ribociclib may stop the growth of tumor cells by blocking some enzymes needed for cell growth. Cancer cells that are estrogen receptor positive may need estrogen to grow. Letrozole lowers the amount of estrogen made by the body and this may stop the growth of tumor cells that need estrogen to grow. Giving ribociclib together with letrozole may be an effective treatment in patients with ovarian, fallopian tube, primary peritoneal, or endometrial cancer.
Key Dates
- Start date
- Jul 8, 2016
- Status verified
- Oct 2021
- Primary completion
- May 21, 2018
- Completion
- Oct 7, 2020
Study Design
- Enrollment
- 40 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Treatment (ribociclib and letrozole)Patients receive ribociclib PO daily and letrozole PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Primary Outcome Measure
Percentage of Patients Alive and Free of Progression at 12 Weeks (PFS12) [ Time Frame: At 12 weeks ]
Locations (3)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Mayo Clinic in Arizona | Scottsdale | Arizona | 85259 | - |
| Mayo Clinic in Florida | Jacksonville | Florida | 32224-9980 | - |
| Mayo Clinic | Rochester | Minnesota | 55905 | - |
Find similar trials in Scottsdale, AZ
Related Studies
- S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast CancerRecruiting · SWOG Cancer Research Network · Anchorage, Alaska
- Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair VariationsPHASE2 · Recruiting · National Cancer Institute (NCI) · Gainesville, Florida
- Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment TrialPHASE2 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialPHASE2 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama